GWAS meta-analysis identifies 44 TIA loci, 19 specific to transient ischemic attackGenetic study identifies new targets for stroke and mini-strokes
medRxivPublished August 6, 2026Study authors: Hu, S.; Zhu, P.; Wu, S.; Gao, S.; Wang, R.; Liu, F.; He, Y.; Han, Z.; Wang, T.; Wang, M.; Ren, C.; J…DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider these TIA loci as associative; validate before clinical use.
This is a meta-analysis of genome-wide association studies (GWAS) investigating the genetic architecture of transient ischemic attack (TIA). The analysis included large samples: 1,332,453 European individuals, 610,409 non-European individuals, and a multi-ancestry group of 1,942,862 individuals. The primary outcome was the identification of TIA-associated loci.
The meta-analysis identified 44 loci associated with TIA, of which 25 were known stroke loci and 19 were TIA-specific. The TIA-specific loci include CELSR2, SLC4A7, CASC15, SRRM3, SLC44A1, LOC107984361, GSE1, LOC105372530, HCG20, OXR1, SLC4A1, RBBP8, TUSC3, DCC, PALMD, ZNF475, CTAGE1, FUT2, and MRPS6. Additionally, the study identified 51 high-confidence genes, with 24 flagged as potential therapeutic targets. Thirteen statistically significant pathways were also identified, including those related to protein-lipid complex, neurofibrillary tangle, and high-density lipoprotein particle.
The authors note that these findings are associative, not causal, and that the biological mechanisms are inferred from pathway analyses. The potential therapeutic targets are described as 'potential' and are not yet confirmed. The study's limitations were not reported in the available information.
For clinicians, this research provides critical insights into the genetic basis of TIA and highlights potential avenues for future therapeutic development. However, given the associative nature of GWAS, these findings should not yet influence clinical practice directly.
How this fits prior evidence
This GWAS meta-analysis extends prior coverage by identifying 44 TIA loci, including 19 TIA-specific ones, which complements earlier findings on stroke-related factors such as sarcopenia risk factors and infarct volume considerations. It provides genetic insights that may eventually inform risk stratification, but unlike prior intervention-focused studies (e.g., early DOAC initiation, emotional interventions, bilateral training), this is an association study without direct clinical application yet.
When someone experiences a transient ischemic attack, or TIA, it is often called a mini-stroke because it serves as a warning sign for a major stroke. Understanding why these events happen is vital for preventing permanent brain damage. Researchers analyzed the DNA of nearly 2 million people from diverse backgrounds to find the genetic roots of these conditions.
The study identified 44 specific locations in the genome linked to TIA and stroke. While some were already known, researchers found 19 unique spots specifically tied to TIAs. They also pinpointed 51 high-confidence genes. Among these, 24 are being looked at as potential targets for future medical treatments.
By mapping out these genetic markers, scientists identified 13 pathways in the body that play a role in brain health. While these results show a strong link between genetics and stroke risk, it is important to remember that these are associations rather than proven causes. These findings provide a roadmap for developing new ways to treat and prevent strokes.
What this means for you:
A large genetic study identified 19 specific markers for mini-strokes and 24 potential targets for future treatment.
Common questions
What is a TIA?
A transient ischemic attack, or TIA, is often called a mini-stroke. It is a temporary blockage of blood flow to the brain that can act as a warning sign for a full stroke.
How many genetic markers were found?
The study identified 44 total loci, which are specific locations in the genome. Of these, 25 were already known to be linked to strokes, while 19 were specifically tied to TIAs.
Are there new ways to treat stroke based on this?
The study identified 51 high-confidence genes. Out of those, 24 are considered potential targets for future therapies, though they are not yet confirmed treatments.
Transient ischemic attack (TIA) is a critical harbinger of subsequent stroke, and most genetic risk remains uncharacterized. Here we firstly performed the largest TIA genome-wide association study (GWAS) meta analysis in 1,332,453 European individuals (58,976 cases and 1,273,477 controls), followed by an independent replication in 610,409 non-European individuals (23,557 TIA and 586,852 controls), a multi-ancestry GWAS meta analysis in 1,942,862 individuals (82,533 cases and 1,860,329 controls), and a cross-trait GWAS meta-analysis of TIA with stroke and its subtypes. We identified 44 loci including 25 known stroke loci and 19 TIA specific loci (CELSR2, SLC4A7, CASC15, SRRM3, SLC44A1, LOC107984361, GSE1, LOC105372530, HCG20, OXR1, SLC4A1, RBBP8, TUSC3, DCC, PALMD, ZNF475, CTAGE1, FUT2 and MRPS6). Post-GWAS pinpointed 51 high confidence genes (24 are potential therapeutic targets) and 13 statistically significant pathways including protein-lipid complex, neurofibrillary tangle, high-density lipoprotein particle. These findings provide critical insights into the genetic basis of TIA.
